CAMP4 Therapeutics Corporation (CAMP) AI Stock Analysis
CAMP AI stock analysis summary
AI ResearchCAMP4 Therapeutics Corporation is a clinical-stage biotechnology company discovering RNA-based treatments for genetic diseases. Over the trailing twelve months, the company generated $4.2M in revenue with an operating margin of -752.1% and net income of -$80.4M in FY2025. It held $84.8M in net cash as of June 30, 2026, while its stock has declined 48.3% year-to-date.
- Market cap
- $198.9M
- Revenue (TTM)
- $4.2M
- P/E
- —
- 1Y return
- 1.9% S&P 500 16.8%
- Avg. target
- $10.25 223.3% vs last close
Bull case
- Wall Street analysts have a mean price target of $10.25, representing 223.3% upside over the last close of $3.17.
- The balance sheet maintains $87.1M in cash and short-term investments with a net cash position of $84.8M as of June 30, 2026.
- Revenue increased 436.5% to $3.5M in FY2025, followed by 18.8% year-over-year revenue growth in the quarter ended June 30, 2026.
Bear case
- Net losses expanded to -$80.4M in FY2025, and operating margin over the trailing twelve months stands at -752.1%.
- CAMP trades at an elevated price-to-sales ratio of 47.2x, significantly higher than the 4.1x median for its US-listed Healthcare peers.
- The company generated negative free cash flow of -$29.8M in FY2025 and carried negative shareholders' equity of -$693,000 as of June 30, 2026.
What CAMP4 Therapeutics does
Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company that discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. In addition, the company develops CMP-002 for the treatment of SYNGAP1-related disorders. Formerly known as Marauder Therapeutics, Inc. until changing its name in March 2018, the company was incorporated in 2015, completed its IPO in 2024, and is headquartered in Cambridge, Massachusetts with 48 employees.
Growth and profitability
Annual revenue decreased from $295.8M in FY2021 and $294.9M in FY2022 to $350,000 in FY2023, reflecting a 5-year revenue CAGR of -59.2% from FY2020 to FY2025. Revenue subsequently grew 86.3% to $652,000 in FY2024 and 436.5% to $3.5M in FY2025. Annual net losses widened from -$28.0M in FY2021 to -$80.4M in FY2025 alongside research and development expense of $38.2M. Over the trailing twelve months, revenue totaled $4.2M with an operating margin of -752.1% and EPS of -$2.35. For the latest quarter ended June 30, 2026, quarterly revenue rose 18.8% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, the company held $87.1M in cash and short-term investments against total debt of $2.4M, resulting in net cash of $84.8M. Total assets stood at $93.4M and the current ratio was 4.70, while shareholders' equity was -$693,000. In FY2025, operating cash flow was -$29.6M and free cash flow was -$29.8M, with capital expenditures of $279,000. Over the past five years, the company's share count grew 63.3%.
Valuation and performance
At its last close of $3.17 on October 16, 2026, CAMP has a market cap of $198.9M and an enterprise value of $150.1M. The stock trades at a price-to-sales multiple of 47.2x and an EV-to-revenue multiple of 35.6x, compared to the median of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 9.1x. Over the past year, CAMP shares gained 1.9%, trailing the S&P 500 (SPY) return of 16.8%. The stock is down 48.3% year-to-date and trades 27.1% below its 200-day average.
What analysts expect
Analyst coverage reflects 6 Strong Buy and 3 Buy ratings, with zero Hold or Sell recommendations. The mean price target is $10.25, representing an implied upside of 223.3% versus the last close of $3.17. For the fiscal year ending December 31, 2026, analysts estimate revenue of $6.4M and EPS of -$1.13. For the next fiscal year, 5 analysts project revenue of $4.9M and EPS of -$0.85. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 5, 2026.
Key risks and what to watch
- Continued cash burn, evidenced by FY2025 free cash flow of -$29.8M, poses ongoing funding requirements against $87.1M in cash.
- A 63.3% increase in share count over 5 years indicates past equity dilution.
- Analyst consensus projects revenue for next fiscal year to decline 22.5% to $4.9M.
- Shareholders' equity remains negative at -$693,000 as of June 30, 2026.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this CAMP AI stock analysis
This page is an AI-written research summary of CAMP4 Therapeutics Corporation (CAMP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: CAMP income statement, CAMP balance sheet, CAMP key metrics, CAMP analyst forecast, CAMP chart. See the CAMP stock overview for the latest quote and news.
CAMP AI stock analysis FAQ
What does CAMP4 Therapeutics Corporation do?
CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company that develops RNA-based therapeutics for genetic diseases, including lead candidates CMP-001 and CMP-002.
Does CAMP pay a dividend?
No, CAMP does not pay a dividend.
What is the consensus analyst price target for CAMP?
The mean analyst price target is $10.25, which sits 223.3% above the stock's closing price of $3.17 on October 16, 2026.
When does CAMP report its next quarterly earnings?
CAMP is scheduled to report its next earnings on November 5, 2026.
How much cash and debt does CAMP carry?
As of June 30, 2026, CAMP had $87.1M in cash and short-term investments, $2.4M in total debt, and net cash of $84.8M.